Tumour-derived apolipoprotein E induces tip endothelial cell to remodel tumour stroma ratio and promote pancreatic neuroendocrine tumour progression

#4424

Introduction: Current clinical trials have shown that single-targeted matrix administration does not improve patient prognosis. The investigation of targeted matrix administration in combination with other therapies is crucial for effectively managing TSR in pNETs.

Aim(s): Although successful preclinical use of polyethylene glycol hyaluronidase (PEGPH20) enzyme degradation of hyaluronic acid (HA) has been reported, but the combination of PEGPH20 with other treatments did not improve overall survival (OS) and progression-free survival (PFS). Thus, there is an urgent need for treatments targeting the tumour stroma.

Materials and methods: Laser capture microdissection (LCM) and proteomic techniques were employed to identify markers associated with TSR. Single-cell sequencing was used to explore the proportion of endothelial cell (EC) in pNETs.

Conference:

Presenting Author: Ji S

Authors: Lou X, Ji S, Xu X, Chen J, Yu X,

Keywords: APOE, pancreatic neuroendocrine tumour, endothelial cell, tumour stroma ratio, mTOR inhibitor,